RT01 / Nanolattix - LARVOL DELTA

RT01: A novel anti-TF, radionuclide drug conjugate (RDC) for theranostic precision oncology (AACR 2026) - "Histopathology analysis of ten major organs (kidney, intestine, brain, lung, liver, femur, spleen, stomach, heart, and pancreas) revealed no observable abnormalities or serious toxicity. In conclusion, the RT01 theranostic pair provides superior tumor targeting, rapid non-target clearance, and a favorable toxicity profile, supporting its continued clinical development for TF-positive cancers."

Oncology